{"pub": "marketwatch", "url": "https://marketwatch.com/articles/letters-to-the-editor-of-barrons-51570233601", "downloaded_at": "2019-10-05 00:23:05.061834+00:00", "title": "Letters to Barron\u2019s", "language": "en", "text": "Biotech Roulette?\n\nTo the Editor:\n\nI wish the roundtable panelists had discussed how scalable the manufacturing processes are for some of these companies (\u201cThe Future of Biotech,\u201d Cover Story, Sept. 27). If you need a whole squad of MDs and Ph.Ds to produce one batch of the product, the costs per patient are not likely to come down. The perfect example was the paragraph about Vertex Pharmaceuticals, where revenue is $3 billion on an estimated patient population of 70,000. That\u2019s about $42,000 per year per patient (and more if...", "description": "Letters on biotech investing, the IPO market, Leon G. Cooperman\u2019s response to a letter in Barron\u2019s,the German economy, and sparing the drugmakers", "authors": [], "top_image": "https://asset.barrons.com/public/resources/images/ON-DC750_Barron_OR_20190712152504.jpg", "published_at": "2019-10-04"}